The modern treatment of cardiovascular diseases with b-blockers - focus on the nebivolol. | Zendy

А. Г. Евдокимова | Zendy; Valeriy Aleksandrovich Ol'khin | Zendy; Vladimir V. Evdokimov | Zendy; Ekaterina Viktorovna Zolotareva | Zendy; А. Б. Хадзегова | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The modern treatment of cardiovascular diseases with b-blockers - focus on the nebivolol.

Author(s) -

А. Г. Евдокимова,

Valeriy Aleksandrovich Ol'khin,

Vladimir V. Evdokimov,

Ekaterina Viktorovna Zolotareva,

А. Б. Хадзегова

Publication year - 2009

Publication title -

systemic hypertension

Language(s) - English

Resource type - Journals

eISSN - 2542-2189

pISSN - 2075-082X

DOI - 10.26442/sg33077

Subject(s) - nebivolol , nitric oxide , medicine , cardiology , pharmacology , blood pressure

Unlike first-line antihypertensives, nebivolol, a cardioselective b-blocker with vasodilatatory properties caused by its ability to modulate the activity of nitric oxide, positively affects prognosis in patients with arterial hypertension and chronic heart failure and shows metabolic neutrality. The clinical and pathogenetic studies demonstrating the benefits of nebivolol are discussed.Keywords: nebivolol, arterial hypertension, b-blockers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research